SCHEMBL3878071

SCHEMBL3878071

Cc1ccc(F)cc1-c1nc(N2CCOCC2)nc(N2CCN(c3ccccn3)CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.51
PIK3CA P42336 6/20 0.47
MTOR P42345 6/20 0.47
PIK3R1 P27986 4/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 2/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
BACE1 P56817 1/20 0.45
AOC3 Q16853 1/20 0.43
POLB P06746 1/20 0.43
DRD4 P21917 3/20 0.42
HTR1A P08908 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884202 0.92 PIK3CA (0.50) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3885540 0.89 BCHE (0.49) LRRK2PIK3CAMTORPIK3R1HPGD
SCHEMBL3887124 0.89 HPGD (0.50) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3878479 0.87 BCHE (0.57) LRRK2PIK3CAMTORPIK3R1HPGD
SCHEMBL3884243 0.87 PIK3CA (0.54) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3878604 0.87 ALDH1A1 (0.52) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3879980 0.84 CNR2 (0.51) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3877480 0.84 PIK3CA (0.51) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3878768 0.83 HPGD (0.47) PIK3CAMTORPIK3R1HPGDHSD17B10
SCHEMBL3887621 0.82 PIK3CA (0.58) PIK3CAMTORPIK3R1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG LRRK2 1804/4885PIK3CA 1107/4885MTOR 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.